MHLW To Add 100 Adverse Event Analysts
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare has put out a new plan to recruit 100 drug adverse effect analysts to strengthen such functions at the Pharmaceutical and Medical Device Agency. PMDA handles drug reviews and post market inspections. The increase will more than double the current 66 analysts who are conducting side effects analysis. The Ministry expects most of the new hires will be physicians, pharmacists and statisticians. As several highly effective cancer and rheumatic drugs have been launched to the market, the Ministry estimates that associated adverse events reports will be on the rise. (Click here for more - Japanese language
You may also be interested in...
Japan Pharmaceutical Trade Association Helps Foot Bill To Speed Up Approval Of Drugs Pending Approval
The Japan Pharmaceutical Manufacturer's Association announced a plan to establish a support center to speed up approvals of drugs not yet approved in Japan. With an annual budget of ¥310 million and staffed with Japanese academics and pharmaceutical industry veterans, the center is opening its doors this month
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.